Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease
Hyperbilirubinemia, Erythroblastosis, Fetal
About this trial
This is an interventional treatment trial for Hyperbilirubinemia focused on measuring Immunoglobulins, Intravenous, Hyperbilirubinemia, Erythroblastosis, Fetal, Exchange Transfusion, Whole Blood
Eligibility Criteria
Inclusion Criteria: All newborns with a gestational age equal or higher than 32 weeks, with a Rh (D) positive blood type, children of sensitized Rh (D) negative mothers, regardless if they were submitted or not to an intra-uterus transfusion. Exclusion Criteria: Newborns in serious condition, hydropic, hemodynamically instable or with indication for exchange transfusion at birth. The indications for exchange transfusion at birth are: presence of bilirubin in the umbilical cord higher or equal to 4mg%; hydrops, cardiac insufficiency secondary to severe anemia.
Sites / Locations
- Maria Elisabeth L Moreira
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Experimental group
CONTROL GROUP
Intravenous Immunoglobulin
Normal Saline solution